|
|
Article: Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference.(Conference news)
- Article from:
- Business Wire
- Article date:
- June 11, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Both Studies Demonstrated Pharmacokinetics Supporting Once-Daily Dosing, with Significant Reduction in Bacterial Infection in Cystic Fibrosis Patients
HAYWARD, Calif. -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 study in healthy volunteers and Phase 2a study of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) patients at the 32nd European Cystic Fibrosis Conference in Brest, France.
POSTER NUMBER: # 196
ABSTRACT TITLE: Pharmacokinetics and Antibacterial Activity of Inhaled Liposomal Ciprofloxacin Hydrochloride in Healthy Volunteers and in Cystic Fibrosis (CF) patients
...